Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a. Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
b. Abemaciclib + Fulvestrant
c. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
d. Atezolizumab +Nab-paclitaxel/Paclitaxel
e. Capecitabine as a single agent
f. Eribulin as a single agent or in combination
g. Everolimus + Exemestane
h. Fulvestrant as a single agent
i. Lapatinib
j. Neratinib
k. Parp Inhibitors (Olaparib/Talazoparib)
l. Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
m. Palbociclib + Fulvestrant
n. Pembrolizumab
o. Platinum (e.g. carboplatin or cisplatin) as a single agent
p. Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
q. Ribociclib + Fulvestrant
r. Sacituzumab Govitecan
s. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
t. Taxane and/or Anthracycline in combination
u. Trastuzumab as a single agent or in combination
v. Trastuzumab emtansine
w. Transtuzumab deruxtecan
x. Any other active systemic anti-cancer therapy
Q2. In the past 3 months, how many early/locally advanced breast cancer (Stages 1 to 3B) patients were treated with:
a. Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
b. Taxane and/or Anthracycline (monotherapy or in combination)
c. Any other active systemic anti-cancer therapy